title: Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines.
abstract: This study describes the synergistic interaction of two biochemical modulators, cyclosporin A (CyA) and verapamil (Vp), in multidrug-resistant cells, the highly resistant and moderately resistant variants (CEM/VLB 1000 and CEM/VLB 100) of the parental drug-sensitive T-cell leukemia cell line CEM/CCRF. In the absence of either modulator, the 50% inhibitory concentration for Adriamycin in these cell lines was 270 +/- 10.6 (SD) micrograms/ml, 96 +/- 8.5 micrograms/ml, and 1.5 +/- 0.1 micrograms/ml, respectively. CyA and Vp dramatically reduced multidrug resistance in CEM/VLB 100 and CEM/VLB 1000 in a dose-dependent manner but had no effect on the sensitivity of the parental line to Adriamycin. At a CyA concentration of 8.3 mumol (10 micrograms/ml), the 50% inhibitory concentration of Adriamycin of CEM/VLB 1000 and CEM/VLB 100 fell to 5.9 +/- 0.9 micrograms/ml and 3.3 +/- 0.6 micrograms/ml, respectively. Similarly at a Vp concentration of 10 mumol the 50% inhibitory concentration of Adriamycin of CEM/VLB 1000 and CEM/VLB 100 fell to 23.7 +/- 3.7 micrograms/ml and 5.7 +/- 0.2 micrograms/ml, respectively. More importantly, CyA and Vp showed significant synergism when tested in combination in the moderately resistant line at concentrations normally seen after the clinical administration of these modulators. Synergy was also present when both drugs were tested in the highly resistant variant. These data indicate the need for in vivo studies, given the potential clinical importance of these observations.
authors.affiliation: Department of Medicine, Repatriation General Hospital, Heidelberg, Victoria, Australia.
authors.forename: X F
authors.initials: XF
authors.lastname: Hu
authors.forename: T J
authors.initials: TJ
authors.lastname: Martin
authors.forename: D R
authors.initials: DR
authors.lastname: Bell
authors.forename: M
authors.initials: M
authors.lastname: de Luise
authors.forename: J R
authors.initials: JR
authors.lastname: Zalcberg
mesh_terms: D003524:Cyclosporins / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004347:Drug Interactions; D004351:Drug Resistance; D006801:Humans; D007945:Leukemia, Lymphoid; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology*
chemical_list: D003524:Cyclosporins; D004273:DNA, Neoplasm; D004317:Doxorubicin; D014700:Verapamil